Quantcast

GenomeDx Expands Insurance Coverage for Decipher® Prostate Cancer Test Through Contract with Prime Health Services

June 16, 2014

SAN DIEGO, June 16, 2014 /PRNewswire/ — GenomeDx Biosciences today announced that it has entered into a contractual agreement as a participating provider with Prime Health Services to provide diagnostic laboratory testing services. GenomeDx, which discovered and developed the Decipher® Prostate Cancer Classifier, will provide laboratory services, making the Decipher test available to members of the Prime Health network, which includes 9 million covered lives. Prime Health payors will provide insurance coverage for patients whose physicians order the Decipher test.

The Decipher Prostate Cancer Classifier directly measures a patient’s biological risk of developing metastatic prostate cancer. Together with existing coverage from other networks, the contract brings coverage of the Decipher prostate cancer test to nearly 120 million lives.

“With a robust package of clinical data related to the performance and clinical utility of Decipher, we’ve shown that the test not only outperforms other tools for predicting cancer metastasis in men who have had a radical prostatectomy, but that this information also impacts treatment decisions in 30-40% of cases,” said Doug Dolginow, MD, CEO of GenomeDx. “That kind of impact can help save healthcare dollars by more accurately assessing patient risk, and helping to guide the right treatment for the right patient.”

About Decipher

The Decipher® Prostate Cancer Classifier directly measures a patient’s biological risk of developing metastatic prostate cancer. By assessing the activity of multiple genomic markers associated with metastatic disease, Decipher provides information about the aggressiveness of a patient’s tumor – information distinct from that provided by PSA and other clinical risk factors. Decipher continues to demonstrate that it can accurately predict aggressive disease and help physicians make more informed treatment decisions for men with prostate cancer.

Decipher is covered by multiple private insurance plans and is available to eligible US patients through their physicians. To learn more about ordering the Decipher test please visit www.deciphertest.com.

About GenomeDx

GenomeDx Biosciences is focused on transforming patient management by putting usable genomic information in the hands of patients and their physicians. GenomeDx has developed the Decipher® Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. To learn more visit www.genomedx.com.

About Prime Health

Founded in 2001 and based in Brentwood, TN, Prime Health Services is a medical cost containment company that offers a full spectrum of services, including a Preferred Provider Organization (PPO) ready for access with customizable solutions and other medical management services. Prime Health’s PPOs include Workers’ Compensation, Group Health, Corrections, Medicare, and Auto Liability networks. Prime Health has over 700,000 providers and facilities nationwide forming the Prime Health National Delivery System. Prime Health offers our National Delivery System to the TPA, insurance carrier, governmental, and self-insured markets. More Information is available at www.primehealthservices.com or by calling 1-866-348-3887.

SOURCE GenomeDx Biosciences


Source: PR Newswire



comments powered by Disqus